MKGAF News 158.0237 Merck Kgaa Dm 5 (MKGAF)

New Post Public Reply Private Reply Replies (0) Message Board

Apr 16, 2014 at 3:53 PM

Merck Kgaa Dm 5 (MKGAF) 158.0237 $MKGAF

Merck KGaA Starts Study on Tecemotide - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 5:55PM CDT
Oncothyreon announced that Merck KGaA commenced a phase III study, START2, on oncology candidate, tecemotide (L-BLP25).

Merck KGaA and Auxogyn Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 4:00PM CDT
Merck KGaA entered into an exclusive license agreement with Auxogyn, Inc. for the Early Embryo Viability Assessment (Eeva) test.

Merck KGaA, Pfizer and Broad Institute Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 03, 4:10PM CDT
Recently, Merck KGaA's biopharmaceutical division, Merck Serono, entered into a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, MA.

Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris

Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.

Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents

Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.

Avanir Reports Wider Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 11, 8:37AM CST
Avanir reported 4Q13 net loss per share of 10 cents, wider than the Zacks Consensus Estimate of a loss of 7 cents

Threshold Pharma's TH-302 in Melanoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 12:00PM CDT
Threshold Pharmaceuticals recently initiated a phase II trial on its pipeline candidate, TH-302.

Update on Threshold Pharma's TH-302 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 08, 10:20PM CDT
Threshold Pharma announced an amendment in the protocol for its pivotal phase III study of TH-302

Sanofi's Lemtrada Gets CHMP Backing - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 01, 11:40AM CDT
The Committee for Medicinal Products for Human Use recommended the approval of Lemtrada

Data on Merck KGaA's L-BLP25 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 22, 9:00PM CDT
Merck KGaA presented detailed results on its oncology candidate L-BLP25, from the phase III study, START.

Merck KGaA Posts Higher Y/Y Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 15, 10:24AM CDT
Merck KGaA reported first quarter 2013 earnings per American Depository Receipt (ADR) of $2.79, up 28.1% year over year.

Merck KGaA-CBRX Renew Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 11, 3:00PM CDT
Merck KGaA and Columbia Labs renewed a license and supply agreement for Crinone (progesterone gel), extending it for an additional five years

Sanofi Reports Lemtrada Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 27, 4:30PM CDT
Sanofi's subsidiary, Genzyme, announced interim data on Lemtrada.

Merck KGaA-BMY Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 21, 4:15PM CDT
Merck KGaA announced a deal with Bristol-Myers Squibb for the promotion of different formulations of Glucophage (metformin hydrochloride) in China.

Merck KGaA - Nordic Bioscience Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 20, 4:00PM CDT
Merck KGaA recently announced a strategic deal with Nordic Bioscience Clinical Development A/S for its pipeline candidate, sprifermin.

Threshold Cuts Loss, Misses Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 13, 9:00AM CDT
Threshold Pharmaceuticals Inc. reported fourth-quarter 2012 net loss per share of 10 cents, narrower than the Zacks Consensus Estimate of a loss of 12 cents.

Strong Quarter for Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 08, 9:40AM CST
Merck KGaA reported fourth quarter 2012 earnings per American Depository Receipt of $2.66, up 18.8% year over year.

Positive Data from BMRN's PKU-016 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 20, 4:50PM CST
BioMarin announced positive results from the PKU-016 ASCEND study.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Voter Events by Valley Community Healthcare Aim to Empower

Here's a game-changer for the community. Valley Community Healthcare (VCH) is stepping up, proving that healthcare doesn't just stick to check-ups and prescriptions. It's about the whole shebang—community empowerment included. This October, VCH is hosting two incredible voter events, collaborating with the Los Angeles County Registrar-Recorder's Mobile Voting Program....

LG OLED evo W6: UAE Roadshow Starts with a Bang

They've done it again, folks. LG Electronics is out there kicking up a storm with their all-new OLED evo W6 True Wireless Wallpaper TV, and they're bringing the action straight to the UAE's doorsteps. Imagine taking a stroll and stumbling upon this technological marvel at some fancy spot like The Lotus Lounge at Anantara The Palm Dubai Resort. This ain't just a TV, it's a...

Hyliion Class Action Deadline Nears for Investors

Potential Shockwaves for Hyliion Investors Investors are having a showdown with Hyliion (NYSE:HYLN) these days. With the looming October 27, 2026, deadline to jump into a securities class action, it seems Hyliion's latest escapade smells worse than a fish market on a hot day. We’ve got allegations here stronger than your uncle’s morning coffee. Understanding the Legal...

Innventure Faces Major Lawsuit Over Misleading Investors

Missteps at Innventure: A Costly Lesson in Investor Trust The stock market is no stranger to drama, but Innventure's saga feels like a page ripped right out of a thriller novel. You’ve got accusations, alleged fabrications, and a swift drop in stock prices that’s left some investors shaking their heads. The company, nestled under the ticker NASDAQ:INV, finds itself...

Weifang's Cultural Resurgence: A Global Epigraphy Fest

A Historical Meltdown into Global Recognition Welcome to the ride where ancient stones talk and cultural borders vanish. We're diving into the beating heart of Weifang, a place you're probably hearing about now because the town's hosting a packed international media tour. And, for a change, this isn't just another tourist trap; it's a cultural adrenaline shot to the arm,...

AEVEX Facing Class Action Deadline Amid Stock Turmoil

Investors are no strangers to the rough and tumble of stock markets, but things get downright messy when trust is shattered. That's the sorry saga unfolding with AEVEX, where shareholders are feeling the heat after a sharp nosedive in stock value. The clock is ticking to join the class action, and any AEVEX investor worth their salt should pay attention. Unraveling...

Masimo's smartSET™ Revolutionizes Patient Monitoring

Breaking Ground in Patient Monitoring Let's dive into the gritty details behind Masimo's latest FDA-nod: the smartSET™ system. This gizmo ain't your ordinary pulse oximeter; it's a next-gen hand-holder for the medical world, poised to ride the AI wave straight into the clinic. They've cracked open a new way for clinicians to peek behind the curtain of patient vitals,...